Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction

N/ACompletedNCT02054390

Ankara University459 enrolled

Overview

Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Study Type

OBSERVATIONAL

Enrollment

459

Conditions

Metabolic Syndrome Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. metabolic syndrome 2. elective percutaneous coronary intervention with angiographically successful stent implantation Exclusion Criteria: 1. acute coronary events 2. renal failure 3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded 4. left main coronary artery disease 5. chronic total occlusion 6. high levels of baseline CKMB or troponin 7. any contraindication of aspirin, clopidogrel or ACEi treatment

Locations (1)

Ankara University School Of Medicine, Department of Cardiology

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

Periprocedural myocardial injury (MI)

Periprocedural MI was defined as cardiac Troponin I release \[5 times ULN\] 24 hours after percutaneous coronary intervention

Time frame: 24 hours after (percutaneous coroary intervention) PCI

Secondary Outcomes

Periprocedural myonecrosis

Peri-procedural myonecrosis was defined as troponin I release of \>1×ULN 24 hours after the intervention.

Time frame: 24 hours after PCI

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.